Loading institutional data...
Loading institutional data...
Held by 2,114 of 5,944 reporting institutions (100th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $92.77 today, the market must believe free cash flow compounds 9.3%/yr for a decade (off $5.3B normalized FCF).
The market's 9.3% is more optimistic than its 9-yr track record.
2-stage DCF · 1.28B shares · net debt -$161M
mean 3.0% · volatility σ 29% · implied rate exceeded in 3/9 yrs
Central path = implied 9.3%/yr growth; shaded band = ±1σ (29%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 67% of free cash flow, leaving room to grow it and fund buybacks. Last year: $3.6B dividends + $1.0B buybacks = $4.7B returned on $5.4B FCF.
9 consecutive years of dividend increases · 6%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Modest payoff on reinvested capital. Current ROIC on all capital: 9%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $1.9B covers the $1.8B due within a year 1.1× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-04-24 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~40.0% on $1.8B of debt.
Cash of $1.9B fully covers short-term debt of $1.8B.
Mostly short-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 30.0 | 32.6 | 34.8 | 32.0 | 34.3 | 34.7 | 34.7 | 35.0 |
| SG&A | 34.1 | 35.0 | 33.7 | 32.5 | 33.4 | 33.2 | 32.3 | 32.4 |
| Operating Income | 20.5 | 16.6 | 14.9 | 18.2 | 17.6 | 15.9 | 17.8 | 17.8 |
| Income Tax | 1.8 | -2.6 | 0.9 | 1.4 | 5.1 | 3.5 | 2.8 | 3.6 |
| Net Income | 15.2 | 16.6 | 12.0 | 15.9 | 12.0 | 11.4 | 13.9 | 13.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MDT: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.36B 100.0% | $33.54B 100.0% | $32.36B 100.0% | $31.23B 100.0% | $31.69B 100.0% | $30.12B 100.0% | $28.91B 100.0% | $30.56B 100.0% | $29.95B 100.0% | $29.71B 100.0% |
| Cost of Revenue | $12.72B 35.0% | $11.63B 34.7% | $11.22B 34.7% | $10.72B 34.3% | $10.14B 32.0% | $10.48B 34.8% | $9.42B 32.6% | $9.15B 30.0% | $9.07B 30.3% | $9.29B 31.3% |
| Gross Profit | — | — | — | — | — | — | — | — | $20.90B 69.8% | $20.42B 68.7% |
| Selling, General & Admin | $11.78B 32.4% | $10.85B 32.3% | $10.74B 33.2% | $10.41B 33.4% | $10.29B 32.5% | $10.15B 33.7% | $10.11B 35.0% | $10.42B 34.1% | $10.24B 34.2% | $10.02B 33.7% |
| Operating Income | $6.47B 17.8% | $5.96B 17.8% | $5.14B 15.9% | $5.49B 17.6% | $5.75B 18.2% | $4.48B 14.9% | $4.79B 16.6% | $6.27B 20.5% | $6.64B 22.2% | $5.38B 18.1% |
| Interest Expense | $715.0M 2.0% | $729.0M 2.2% | $719.0M 2.2% | $636.0M 2.0% | $553.0M 1.7% | $925.0M 3.1% | $1.09B 3.8% | $1.44B 4.7% | $1.15B 3.8% | $1.09B 3.7% |
| Interest & Investment Income | — | — | — | — | — | — | — | — | $397.0M 1.3% | $366.0M 1.2% |
| Other Income (Expense), net | $384.0M 1.1% | $402.0M 1.2% | $412.0M 1.3% | $515.0M 1.6% | $318.0M 1.0% | $336.0M 1.1% | $356.0M 1.2% | $373.0M 1.2% | -$505.0M -1.7% | -$222.0M -0.7% |
| Pretax Income | $6.14B 16.9% | $5.63B 16.8% | $4.84B 14.9% | $5.36B 17.2% | $5.52B 17.4% | $3.90B 12.9% | $4.05B 14.0% | $5.20B 17.0% | $5.67B 18.9% | $4.60B 15.5% |
| Income Tax Expense | $1.30B 3.6% | $936.0M 2.8% | $1.13B 3.5% | $1.58B 5.1% | $456.0M 1.4% | $265.0M 0.9% | -$751.0M -2.6% | $547.0M 1.8% | $2.58B 8.6% | $578.0M 1.9% |
| Net Income | $4.80B 13.2% | $4.66B 13.9% | $3.68B 11.4% | $3.76B 12.0% | $5.04B 15.9% | $3.61B 12.0% | $4.79B 16.6% | $4.63B 15.2% | $3.10B 10.4% | $4.03B 13.6% |
| Per Share | ||||||||||
| EPS (Basic) | $3.75 | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 | $3.57 | $3.44 | $2.29 | $2.92 |
| EPS (Diluted) | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 |
| Weighted Avg Shares (Basic) | 1.28B | 1.29B | 1.33B | 1.33B | 1.34B | 1.34B | 1.34B | 1.35B | 1.36B | 1.38B |
| Weighted Avg Shares (Diluted) | 1.29B | 1.29B | 1.33B | 1.33B | 1.35B | 1.35B | 1.35B | 1.36B | 1.37B | 1.39B |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
Peers = companies sharing MDT's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.